Renin-angiotensin-aldosterone system blockers after KDIGO stage 3 acute kidney injury: use and impact on 2-year mortality in the AKIKI trial.
Mathilde ScartonAnne OppenheimerKhalil ChaïbiDidier DreyfussStephane GaudryPublished in: Critical care (London, England) (2019)